← Back to Search

Monoclonal Antibodies

Bexmarilimab for Cancer (MATINS Trial)

Phase 1 & 2
Waitlist Available
Led By Petri Bono, MD, PhD
Research Sponsored by Faron Pharmaceuticals Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Life expectancy > 12 weeks
Histologically confirmed advanced (inoperable or metastatic) malignancies without standard therapeutic options available:
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to six years
Awards & highlights

MATINS Trial Summary

This trial is testing whether a new drug, FP-1305, is suitable for use in humans. The drug is being tested on patients with advanced cancer who have exhausted all other treatment options. The drug works by binding to a receptor called CLEVER-1, which is known to support tumor growth. Previous studies in animals have shown that FP-1305 is safe and effective, and the dose being used in this trial is 300 times lower than the dose that was safe in animals.

MATINS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are expected to live for at least 12 more weeks.
Select...
You have advanced cancer that cannot be treated with standard therapies.
Select...
You have been diagnosed with gallbladder cancer or a specific type of liver cancer called cholangiocarcinoma.

MATINS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose limiting toxicities (DLT) in the trial subjects.
Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)
The response (ORR, CBR and irORR) to the treatment.

MATINS Trial Design

6Treatment groups
Experimental Treatment
Group I: FP-1305 (bexmarilimab) 30 mg/kgExperimental Treatment1 Intervention
Part II Dose-escalation FP-1305 30 mg/kg is administered in Q3W, Q2W or Q1W intervals
Group II: FP-1305 (bexmarilimab) 3 mg/kgExperimental Treatment1 Intervention
Part I and II, Dose-escalation FP-1305 3 mg/kg is administered in Q3W, Q2W or Q1W intervals
Group III: FP-1305 (bexmarilimab) 10 mg/kgExperimental Treatment1 Intervention
Part I and II, Dose-escalation FP-1305 10 mg/kg is administered in Q3W, Q2W or Q1W intervals
Group IV: FP-1305 (bexmarilimab) 1 mg/kgExperimental Treatment1 Intervention
Part I and II, Dose-escalation FP-1305 1 mg/kg is administered in Q3W, Q2W or Q1W intervals
Group V: FP-1305 (bexmarilimab) 0.3 mg/kgExperimental Treatment1 Intervention
Part I, Dose-escalation FP-1305 0.3 mg/kg is administered in Q3W intervals
Group VI: FP-1305 (bexmarilimab) 0.1 mg/kgExperimental Treatment1 Intervention
Part I Dose-escalation FP-1305 0.1 mg/kg is administered in three-week intervals
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bexmarilimab
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Faron Pharmaceuticals LtdLead Sponsor
8 Previous Clinical Trials
590 Total Patients Enrolled
Petri Bono, MD, PhDPrincipal InvestigatorTerveystalo Ltd

Media Library

FP-1305 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03733990 — Phase 1 & 2
Cancer Research Study Groups: FP-1305 (bexmarilimab) 0.3 mg/kg, FP-1305 (bexmarilimab) 1 mg/kg, FP-1305 (bexmarilimab) 3 mg/kg, FP-1305 (bexmarilimab) 10 mg/kg, FP-1305 (bexmarilimab) 0.1 mg/kg, FP-1305 (bexmarilimab) 30 mg/kg
Cancer Clinical Trial 2023: FP-1305 Highlights & Side Effects. Trial Name: NCT03733990 — Phase 1 & 2
FP-1305 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03733990 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To the best of your knowledge, has this type of clinical trial been conducted before?

"The development of FP-1305 began in 2018 with a study that was funded by Faron Pharmaceuticals Ltd. Since then, the medication has undergone Phase 1 & 2 clinical trials and 700 patients have been involved in total. Now, there are 2 ongoing trials in 2 cities and 6 nations."

Answered by AI

How many people can still join this trial?

"This investigation, which was originally advertised on December 3rd, 2018, is still looking for participants according to the clinicaltrials.gov website."

Answered by AI

To what extent has FP-1305 been researched in the past?

"At present time, there are 2 ongoing clinical trials investigating FP-1305 with 0 trials in Phase 3. While many of the clinical trials for FP-1305 are based in Oulu, Texas, there are 12 locations worldwide operating clinical trials for FP-1305."

Answered by AI
Recent research and studies
~35 spots leftby Mar 2025